Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

Science Translational Medicine

Volumn 7, Issue 283, 2015, Pages

  Semeraro, Michaela ^a,b,c,d,e,f   Rusakiewicz, Sylvie ^a,b,g   Minard Colin, Véronique ^a,b,c   Delahaye, Nicolas F ^a,b   Enot, David ^a,e,f   Vély, Frédéric ^h,i,j   Marabelle, Aurélien ^k   Papoular, Benjamin ^a,b   Piperoglou, Christelle ^j   Ponzoni, Mirco ^l   Perri, Patrizia ^l   Tchirkov, Andrei ^m,n   Matta, Jessica ^h,i   Lapierre, Valérie ^a,c   Shekarian, Tala ^k   Valsesia Wittmann, Sandrine ^k   Commo, Frédéric ^a,b   Prada, Nicole ^a,b   Poirier Colame, Vichnou ^a,b   Bressac, Brigitte ^c   Cotteret, Sophie ^a,b   Brugieres, Laurence ^a,c   Farace, Françoise ^a,o   Chaput, Nathalie ^a,b,g   Kroemer, Guido ^a,e,f,p,q   Valteau Couanet, Dominique ^a,b,c   Zitvogel, Laurence ^a,b,d,g   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b University Paris XI   (France)

^c GRCC   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f INSERM   (France)

^g Center of Clinical Investigations in Biotherapies of Cancer   (France)

^h CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j HÔPITAL DE LA CONCEPTION   (France)

^k UNIVERSITÉ DE LYON   (France)

^l G GASLINI INSTITUTE   (Italy)

^m CENTRE JEAN PERRIN   (France)

ⁿ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^o Universite Paris Sud   (France)

^p UNIVERSITÉ PARIS DESCARTES   (France)

^q HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B7 H6 PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; MEMBRANE PROTEIN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; B7 ANTIGEN; LIGAND; NCR3 PROTEIN, HUMAN; NCR3LG1 PROTEIN, HUMAN; PROTEIN BINDING; TUMOR MARKER;

AGE; ARTICLE; BONE MARROW METASTASIS; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CELL FUNCTION; CELL POLARITY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; EVENT FREE SURVIVAL; GENE AMPLIFICATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; METASTASIS POTENTIAL; MULTIMODAL CHEMOTHERAPY; NATURAL KILLER CELL; NEUROBLASTOMA; ONCOGENE C MYB; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; ADOLESCENT; ADULT; BRAIN TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; JURKAT CELL LINE; METABOLISM; METASTASIS; MORTALITY; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDY; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7 ANTIGENS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; JURKAT CELLS; LIGANDS; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NEOPLASM METASTASIS; NEUROBLASTOMA; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN BINDING; RISK FACTORS; YOUNG ADULT;

EID: 84928253171     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa2327     Document Type: Article

References (57)

1. H. Shimada, D. O. Stram, J. Chatten, V. V. Joshi, Y. Hachitanda, G. M. Brodeur, J. N. Lukens, K. K. Matthay, R. C. Seeger, Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J. Natl. Cancer Inst. 87, 1470-1476 (1995).
2. M. L. Schmidt,A. Lal, R. C. Seeger, J. M. Maris, H. Shimada,M.O'Leary, R. B. Gerbing, K. K. Matthay, Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: A Children's Cancer Group Study. J. Clin. Oncol. 23, 6474-6480 (2005).
3. A. D. Pearson, C. R. Pinkerton, I. J. Lewis, J. Imeson, C. Ellershaw, D. Machin; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group), High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol. 9, 247-256 (2008).
4. D. Valteau-Couanet, J. Michon, A. Boneu, C. Rodary, Y. Perel, C. Bergeron, H. Rubie, C. Coze, D. Plantaz, F. Bernard, P. Chastagner, J. Bouzy, O. Hartmann, Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J. Clin. Oncol. 23, 532-540 (2005).
5. K. K.Matthay, C. P. Reynolds, R. C. Seeger,H. Shimada, E. S. Adkins, D. Haas-Kogan, R. B. Gerbing, W. B. London, J. G. Villablanca, Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study. J. Clin. Oncol. 27, 1007-1013 (2009).
6. I. E. Hellstrom, K. E. Hellstrom, G. E. Pierce, A. H. Bill, Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc. Natl. Acad. Sci. U.S.A. 60, 1231-1238 (1968).
7. A. E. Evans, J. Gerson, L. Schnaufer, Spontaneous regression of neuroblastoma. Natl. Cancer Inst. Monogr. 44, 49-54 (1976).
8. R. C. Seeger, Immunology and immunotherapy of neuroblastoma. Semin. Cancer Biol. 21, 229-237 (2011).
9. I. Prigione, M. V. Corrias, I. Airoldi, L. Raffaghello, F. Morandi, P. Bocca, C. Cocco, S. Ferrone, V. Pistoia, Immunogenicity of human neuroblastoma. Ann. N. Y. Acad. Sci. 1028, 69-80 (2004).
10. A. L. Yu, A. L. Gilman, M. F. Ozkaynak, W. B. London, S. G. Kreissman, H. X. Chen, M. Smith, B. Anderson, J. G. Villablanca, K. K. Matthay, H. Shimada, S. A. Grupp, R. Seeger, C. P. Reynolds, A. Buxton, R. A. Reisfeld, S. D. Gillies, S. L. Cohn, J. M. Maris, P. M. Sondel; Children's Oncology Group, Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324-1334 (2010).
11. C. U. Louis, B. Savoldo, G. Dotti, M. Pule, E. Yvon, G. D. Myers, C. Rossig, H. V. Russell, O. Diouf, E. Liu, H. Liu, M. F. Wu, A. P. Gee, Z. Mei, C. M. Rooney, H. E. Heslop, M. K. Brenner, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050-6056 (2011).
12. I. A. Haagen, A. J. Geerars, W. B. de Lau, B. J. Bast, B. C. de Gast, The efficacy of CD3×CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: The effect of repeated addition of BsAb and interleukin-2. Blood 85, 3208-3212 (1995).
13. Y. Liu, H. W. Wu, M. A. Sheard, R. Sposto, S. S. Somanchi, L. J. Cooper, D. A. Lee, R. C. Seeger, Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin. Cancer Res. 19, 2132-2143 (2013).
14. S. Sivori, S. Parolini, E. Marcenaro, R. Castriconi, D. Pende, R. Millo, A. Moretta, Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J. Neuroimmunol. 107, 220-225 (2000).
15. R. Castriconi, A. Dondero, M. V. Corrias, E. Lanino, D. Pende, L. Moretta, C. Bottino, A. Moretta, Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: Critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 64, 9180-9184 (2004).
16. R. K. Yang, N. A. Kalogriopoulos, A. L. Rakhmilevich, E. A. Ranheim, S. Seo, K. Kim, K. L. Alderson, J. Gan, R. A. Reisfeld, S. D. Gillies, J. A. Hank, P. M. Sondel, Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J. Immunol. 189, 2656-2664 (2012).
17. D. C. Delgado, J. A. Hank, J. Kolesar, D. Lorentzen, J. Gan, S. Seo, K. Kim, S. Shusterman, S. D. Gillies, R. A. Reisfeld, R. Yang, B. Gadbaw, K. B. DeSantes, W. B. London, R. C. Seeger, J. M. Maris, P. M. Sondel, Genotypes of NK cell KIR receptors, their ligands, and Fcg receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 70, 9554-9561 (2010).
18. S. E. Chisholm, K. Howard, M. V. Gomez, H. T. Reyburn, Expression of ICP0 is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J. Infect. Dis. 195, 1160-1168 (2007).
19. C. L. Fuller, G. Ruthel, K. L. Warfield, D. L. Swenson, C. M. Bosio, M. J. Aman, S. Bavari, NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell. Microbiol. 9, 962-976 (2007).
20. E. Mavoungou, J. Held, L. Mewono, P. G. Kremsner, A Duffy binding-like domain is involved in the NKp30-mediated recognition of Plasmodium falciparum-arasitized erythrocytes by natural killer cells. J. Infect. Dis. 195, 1521-1531 (2007).
21. D. Mavilio, G. Lombardo, A. Kinter, M. Fogli, A. La Sala, S. Ortolano, A. Farschi, D. Follmann, R. Gregg, C. Kovacs, E. Marcenaro, D. Pende, A. Moretta, A. S. Fauci, Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 203, 2339-2350 (2006).
22. A. Poggi, C. Prevosto, M. Zancolli, P. Canevali, A. Musso, M. R. Zocchi, NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells. Ann. N. Y. Acad. Sci. 1109, 47-57 (2007).
23. M. J. Neville, R. D. Campbell, A new member of the Ig superfamily and a V-ATPase G subunit are among the predicted products of novel genes close to the TNF locus in the human MHC. J. Immunol. 162, 4745-4754 (1999).
24. A. De Maria, M. Fogli, S. Mazza, M. Basso, A. Picciotto, P. Costa, S. Congia, M. C. Mingari, L. Moretta, Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur. J. Immunol. 37, 445-455 (2007).
25. R. Vankayalapati, A. Garg, A. Porgador, D. E. Griffith, P. Klucar, H. Safi, W. M. Girard, D. Cosman, T. Spies, P. F. Barnes, Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J. Immunol. 175, 4611-4617 (2005).
26. C. Fauriat, S. Just-Landi, F. Mallet, C. Arnoulet, D. Sainty, D. Olive, R. T. Costello, Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109, 323-330 (2007).
27. G. Ferlazzo, M. L. Tsang, L. Moretta, G. Melioli, R. M. Steinman, C. Münz, Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195, 343-351 (2002).
28. M. Vitale, M. Della Chiesa, S. Carlomagno, D. Pende, M. Aricò, L. Moretta, A. Moretta, NKdependent DC maturation is mediated by TNFa and IFNg released upon engagement of the NKp30 triggering receptor. Blood 106, 566-571 (2005).
29. A. Byrd, S. C. Hoffmann, M. Jarahian, F. Momburg, C. Watzl, Expression analysis of the ligands for the natural killer cell receptors NKp30 and NKp44. PLOS One 2, e1339 (2007).
30. E. Pogge von Strandmann, VR Simhadri, B. von Tresckow, S. Sasse, K. S. Reiners, H. P. Hansen, A. Rothe, B. Böll, V. L. Simhadri, P. Borchmann, P. J. McKinnon, M. Hallek, A. Engert, Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27, 965-974 (2007).
31. C. S. Brandt, M. Baratin, E. C. Yi, J. Kennedy, Z. Gao, B. Fox, B. Haldeman, C. D.Ostrander, T. Kaifu, C. Chabannon, A.Moretta, R.West, W. Xu, E. Vivier, S. D. Levin, The B7 familymember B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495-1503 (2009).
32. N. F. Delahaye, S. Rusakiewicz, I. Martins, C. Ménard, S. Roux, L. Lyonnet, P. Paul, M. Sarabi, N. Chaput, M. Semeraro, V. Minard-Colin, V. Poirier-Colame, K. Chaba, C. Flament, V. Baud, H. Authier, S. Kerdine-Römer, M. Pallardy, I. Cremer, L. Peaudecerf, B. Rocha, D. Valteau-Couanet, J. C. Gutierrez, J. A. Nunès, F. Commo, S. Bonvalot, N. Ibrahim, P. Terrier, P. Opolon, C. Bottino, A. Moretta, J. Tavernier, P. Rihet, J. M. Coindre, J. Y. Blay, N. Isambert, J. F. Emile, E. Vivier, A. Lecesne, G. Kroemer, L. Zitvogel, Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17, 700-707 (2011).
33. P. Brinkrolf, S. Landmeier, B. Altvater, C. Chen, S. Pscherer, A. Rosemann, A. Ranft, U. Dirksen, H. Juergens, C. Rossig, A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int. J. Cancer 125, 879-886 (2009).
34. A. Schwarzer, B. Wolf, J. L. Fisher, T. Schwaab, S. Olek, U. Baron, C. R. Tomlinson, J. D. Seigne, N. A. Crosby, J. Gui, T. H. Hampton, C. E. Fadul, J. A. Heaney, M. S. Ernstoff, Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy. PLOS One 7, e46600 (2012).
35. V. Castel, P. García-Miguel, A. Cañete, C. Melero, A. Navajas, J. I. Ruíz-Jiménez, S. Navarro, M. D. Badal, Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting. Eur. J. Cancer 35, 606-611 (1999).
36. T. Kaifu, B. Escaliere, L. N. Gastinel, E. Vivier, M. Baratin, B7-H6/NKp30 interaction: A mechanism of alerting NK cells against tumors. Cell. Mol. Life Sci. 68, 3531-3539 (2011).
37. J. Matta, M. Baratin, L. Chiche, J. M. Forel, C. Cognet, G. Thomas, C. Farnarier, C. Piperoglou, L. Papazian, D. Chaussabel, S. Ugolini, F. Vély, E. Vivier, Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 122, 394-404 (2013).
38. B. Decarolis, C. Schneider, B. Hero, T. Simon, R. Volland, F. Roels, M. Dietlein, F. Berthold, M. Schmidt, Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: Results of the Cologne interscore comparison study. J. Clin. Oncol. 31, 944-951 (2013).
39. N. Prada, G. Antoni, F. Commo, S. Rusakiewicz, M. Semeraro, F. Boufassa, O. Lambotte, L. Meyer, M. L. Gougeon, L. Zitvogel, Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 2, e23472 (2013).
40. C. Ménard, J. Y. Blay, C. Borg, S. Michiels, F. Ghiringhelli, C. Robert, C. Nonn, N. Chaput, J. Taïeb, N. F. Delahaye, C. Flament, J. F. Emile, C. A. Le, L. Zitvogel, Natural killer cell IFN-g levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 69, 3563-3569 (2009).
41. C. Borg, M. Terme, J. Taïeb, C. Ménard, C. Flament, C. Robert, K. Maruyama, H. Wakasugi, E. Angevin, K. Thielemans, C. A. Le, V. Chung-Scott, V. Lazar, I. Tchou, F. Crépineau, F. Lemoine, J. Bernard, J. A. Fletcher, A. Turhan, J. Y. Blay, A. Spatz, J. F. Emile, M. C. Heinrich, S. Mécheri, T. Tursz, L. Zitvogel, Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114, 379-388 (2004).
42. N. Zhang, A. J. Sanders, L. Ye, W. G. Jiang, Vascular endothelial growth inhibitor in human cancer (Review). Int. J. Mol. Med. 24, 3-8 (2009).
43. L. S. Metelitsa, H. W. Wu, H. Wang, Y. Yang, Z. Warsi, S. Asgharzadeh, S. Groshen, S. B. Wilson, R. C. Seeger, Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199, 1213-1221 (2004).
44. S. Asgharzadeh, J. A. Salo, L. Ji, A. Oberthuer, M. Fischer, F. Berthold, M. Hadjidaniel, C. W. Liu, L. S. Metelitsa, R. Pique-Regi, P. Wakamatsu, J. G. Villablanca, S. G. Kreissman, K. K. Matthay, H. Shimada, W. B. London, R. Sposto, R. C. Seeger, Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J. Clin. Oncol. 30, 3525-3532 (2012).
45. S. Rusakiewicz, M. Semeraro, M. Sarabi, M. Desbois, C. Locher, R. Mendez, N. Vimond, A. Concha, F. Garrido, N. Isambert, L. Chaigneau, B.-L. V. Le, P. Dubreuil, I. Cremer, A. Caignard, V. Poirier-Colame, K. Chaba, C. Flament, N. Halama, D. Jäger, A. Eggermont, S. Bonvalot, F. Commo, P. Terrier, P. Opolon, J. F. Emile, J. M. Coindre, G. Kroemer, N. Chaput, C. A. Le, J. Y. Blay, L. Zitvogel, Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 73, 3499-3510 (2013).
46. V. P. Balachandran, M. J. Cavnar, S. Zeng, Z. M. Bamboat, L. M. Ocuin, H. Obaid, E. C. Sorenson, R. Popow, C. Ariyan, F. Rossi, P. Besmer, T. Guo, C. R. Antonescu, T. Taguchi, J. Yuan, J. D. Wolchok, J. P. Allison, R. P. DeMatteo, Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17, 1094-1100 (2011).
47. D. Valteau-Couanet, H. Rubie, V. Meresse, F. Farace, M. Brandely, O. Hartmann, Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant. 16, 515-520 (1995).
48. J. B. Bartlett, K. Dredge, A. G. Dalgleish, The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4, 314-322 (2004).
49. S. L. Berg, M. S. Cairo, H. Russell, J. Ayello, A. M. Ingle, H. Lau, N. Chen, P. C. Adamson, S.M. Blaney, Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: A Children's Oncology Group Phase I Consortium report. J. Clin. Oncol. 29, 316-323 (2011).
50. L. Raffaghello, I. Prigione, I. Airoldi, M. Camoriano, I. Levreri, C. Gambini, D. Pende, A. Steinle, S. Ferrone, V. Pistoia, Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6, 558-568 (2004)
51. F. Morandi, I. Levreri, P. Bocca, B. Galleni, L. Raffaghello, S. Ferrone, I. Prigione, V. Pistoia, Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 67, 6433-6441 (2007).
52. L. Song, S. Asgharzadeh, J. Salo, K. Engell, H. W. Wu, R. Sposto, T. Ara, A. M. Silverman, Y. A. DeClerck, R. C. Seeger, L. S.Metelitsa, Va24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 119, 1524-1536 (2009).
53. K. Rakhra, P. Bachireddy, T. Zabuawala, R. Zeiser, L. Xu, A. Kopelman, A. C. Fan, Q. Yang, L. Braunstein, E. Crosby, S. Ryeom, D. W. Felsher, CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485-498 (2010).
54. L. Song, T. Ara, H. W. Wu, C. W. Woo, C. P. Reynolds, R. C. Seeger, Y. A. DeClerck, C. J. Thiele, R. Sposto, L. S. Metelitsa, Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J. Clin. Invest. 117, 2702-2712 (2007).
55. N. Azad, C. A. Zahnow, C. M. Rudin, S. B. Baylin, The future of epigenetic therapy in solid tumours-Lessons from the past. Nat. Rev. Clin. Oncol. 10, 256-266 (2013).
56. J. P. Deroose, A. M. Eggermont, A. N. van Geel, J. W. Burger, M. A. den Bakker, J. H. de Wilt, C. Verhoef, Long-term results of tumor necrosis factor a-and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J. Clin. Oncol. 29, 4036-4044 (2011).
57. G. K. Smyth, J. Michaud, H. S. Scott, Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21, 2067-2075 (2005).